drugset / Trial / NCT05169008
A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents
NaSingle-groupOpen-labelPrevention
Summary
This is a multicenter, randomized, and open-label study to evaluate the immune responses and safety profiles of children aged 6-12 years and adolescents aged 13-17 years receiving Ad5-nCoV (intramuscular injection) or Ad5-nCoV-IH (nebulized inhalation) ≥ 90 days after receiving two doses of CoronaVac.
Timeline
- Start
- 2022-02-25
- Primary completion
- 2023-01-13
- Completion
- 2023-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad5-nCoV | Vaccine | — | Intramuscular |
| Subject | Ad5-nCoV-IH | Vaccine | — | Inhaled |